Trade
Basic
Futures
Futures
Hundreds of contracts settled in USDT or BTC
TradFi
Gold
Trade global traditional assets with USDT in one place
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Participate in events to win generous rewards
Demo Trading
Use virtual funds to experience risk-free trading
Earn
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and enjoy airdrop rewards!
Futures Points
Earn futures points and claim airdrop rewards
Investment
Simple Earn
Earn interests with idle tokens
Auto-Invest
Auto-invest on a regular basis
Dual Investment
Buy low and sell high to take profits from price fluctuations
Soft Staking
Earn rewards with flexible staking
Crypto Loan
0 Fees
Pledge one crypto to borrow another
Lending Center
One-stop lending hub
VIP Wealth Hub
Customized wealth management empowers your assets growth
Private Wealth Management
Customized asset management to grow your digital assets
Quant Fund
Top asset management team helps you profit without hassle
Staking
Stake cryptos to earn in PoS products
Smart Leverage
New
No forced liquidation before maturity, worry-free leveraged gains
GUSD Minting
Use USDT/USDC to mint GUSD for treasury-level yields
More
Hims & Hers Launches New Pill That Sends Shockwaves Across Weight-Loss Drugmakers' Stocks
Key Takeaways
Investopedia Answers
ASK
A new pill from Hims & Hers Health is rattling shares of leading weight-loss drugmakers.
Shares of Eli Lilly (LLY) and Novo Nordisk (NVO) each slipped about 8% Thursday after Hims & Hers said it would start selling a compounded weight-loss pill, at a lower price than rivals. Hims & Hers (HIMS) shares initially surged close to 14%, before reversing course to finish nearly 4% lower.
Hims & Hers said the new pill starts at $49 per month for five months, and comes with the same active ingredient as Novo Nordisk’s Wegovy, which received FDA approval in December and costs $149 for self-pay patients, according to the company’s website.
The new Hims & Hers pill could challenge Novo Nordisk’s Wegovy, and the Danish drugmaker said it plans to take legal action in a statement.
Why This Matters to Investors
Hims & Hers has run into conflicts with Eli Lilly and Novo Nordisk with its compounded weight-loss offerings previously. Thursday’s stock moves could point to concerns about the new product’s impact, as well as responses to its launch.
The announcement comes a day after Eli Lilly and Novo Nordisk shares moved in opposite directions following their latest earnings reports, as Novo Nordisk warned of sales could decline this year, while Eli Lilly said its sales are expected to keep growing.
Eli Lilly said Wednesday that it expects to start selling its own oral weight-loss medication in the second quarter of this year, assuming it gets approved by the FDA, which would add another competitor to Novo Nordisk’s Wegovy pill and Hims & Hers’ new compounded pill.
Related Education
Why Weight-Loss Drugs Could Be Game-Changers for Your Investment Portfolio
How to Save on Weight Loss Drugs: Navigating Insurance and Discounts
With Thursday’s moves, shares of Hims & Hers have are down more than 40% over the past 12 months. Novo Nordisk shares have lost roughly half their value over the same period, while Eli Lilly shares have added about 17%.
Do you have a news tip for Investopedia reporters? Please email us at
[email protected]